secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001140361-25-008559
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys gets CE mark for FemBloc delivery system in Europe, polymer approval expected mid-2025
--------------------------------------------------------------------------------

- FemBloc delivery system receives first-in-world CE mark certification under EU MDR for non-surgical permanent birth control.
- FemBloc blended polymer completes G12 Special MDR Audit; Notified Body recommends CE mark pending EMA review, approval expected mid-2025.
- Company continues enrolling participants in FDA IDE-approved pivotal clinical trial for U.S. approval of FemBloc.
- CEO Kathy Lee-Sepsick highlights FemBloc as a safer, accessible alternative to surgical sterilization, the only option today.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125008559/0001140361-25-008559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036125008559/ef20045446_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-008559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer